Compare WEYS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | BCYC |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.9M | 310.7M |
| IPO Year | 1995 | 2019 |
| Metric | WEYS | BCYC |
|---|---|---|
| Price | $34.54 | $4.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 12.0K | ★ 356.1K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $276,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.25 | $4.24 |
| 52 Week High | $35.69 | $9.36 |
| Indicator | WEYS | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 38.55 |
| Support Level | $30.62 | $4.24 |
| Resistance Level | N/A | $5.31 |
| Average True Range (ATR) | 1.38 | 0.21 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 75.59 | 19.27 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, South Africa, and Australia.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.